Biomarkers to assess disease progression are in use, but none can predict which therapy will work best for each patient
The Rheumatologist as Detective
A case of difficult-to-diagnose Whipple’s disease
2014 ACR/ARHP Annual Meeting: Lung Fibrosis
New drugs, targeted treatments for idiopathic pulmonary fibrosis
Hepatitis C Virus Infection Associated with Rheumatoid Arthritis
Research finds patients with chronic HCV infection more likely to develop RA, especially men
Shorter Antibiotic Therapy Effective for Pyogenic Vertebral Osteomyelitis
Six-week treatment regimen returns same results as 12 weeks in recent study, although researchers caution findings may not apply to all patients with vertebral osteomyelitis
Genetic Risk Factors for Rheumatoid Arthritis Merit More Research
New report determines additional risk factors need to be identified, studied before RA heritability can be fully explained
2014 ACR/ARHP Annual Meeting: Rheumatology Drug Updates, Safety News
Plus, hydrocodone combination products and brodalumab
The ACR/ARHP Annual Meeting: Rheumatoid Arthritis Raises Mortality Risk in Women
Data from Nurses’ Health Study, other clinical trials point to higher risk of respiratory, cardiovascular disease death in women with RA
2014 ACR/ARHP Annual Meeting: Fat’s Role in Inflammation
How obesity, metabolic stress, inflammation contribute to rheumatic diseases
2014 ACR/ARHP Annual Meeting: Predicting Outcomes for Patients with Lupus Nephritis
Better understanding of kidney inflammation and fibrosis in LN, along with finding novel disease biomarkers could help rheumatologists gauge patients’ response to therapy
- « Previous Page
- 1
- …
- 270
- 271
- 272
- 273
- 274
- …
- 345
- Next Page »